Press Releases

- FDA has assigned a PDUFA date of October 24, 2017 -

- ACT CF trial missed primary and secondary endpoints -
- Company to host conference call today, March 2nd at 9:00 am ET -

SOUTH PLAINFIELD, N.J. , Feb. 28, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2016 financial results and provide an update on the company's business and outlook on Tuesday,

SOUTH PLAINFIELD, N.J. , Feb. 21, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on February 20, 2017 it approved non-statutory stock options to purchase an aggregate of 55,900 shares of its common stock to 14 new employees.

-Grant Proposals from Nonprofit Patient Advocacy Organizations Due May 31, 2017-

SOUTH PLAINFIELD, N.J. , Jan. 9, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) announced that it received notification today from the European Commission (EC) of its adoption of a positive decision granting annual renewal of the conditional marketing authorization for Translarna ™

- Preliminary 2016 Translarna unaudited net sales of approximately $81M, a 140% increase vs. 2015 -
- Strategic update for Translarna regulatory path in the U.S. -
- Topline ACT CF data anticipated late first quarter 2017 -
- SMA program actively enrolling patients across SUNFISH and FIREFISH trials -
- RG7916 granted orphan-drug designation for the treatment of SMA -
- Translarna 2017 net sales guidance of $105M to $125M -

SOUTH PLAINFIELD, N.J. , Jan. 6, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to RG7916 for the treatment of patients with Spinal Muscular Atrophy (SMA).

SOUTH PLAINFIELD, N.J. , Jan. 5, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  ( NASDAQ : PTCT) today announced that on January 3, 2017 it approved non-statutory stock options to purchase 4,000 shares of its common stock to one new employee. The award was made pursuant to the NASDAQ inducement

SOUTH PLAINFIELD, N.J. , Jan. 5, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) initiated a clinical study in infants with Type I SMA.